Scancell Holdings plc (LON:SCLP – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 15.04 and traded as low as GBX 13. Scancell shares last traded at GBX 13.40, with a volume of 786,915 shares.
Scancell Price Performance
The stock has a market cap of £137.51 million, a price-to-earnings ratio of -24.09 and a beta of 0.74. The company has a current ratio of 0.56, a quick ratio of 13.01 and a debt-to-equity ratio of -193.29. The company’s fifty day moving average is GBX 19.51 and its two-hundred day moving average is GBX 15.02.
Scancell Company Profile
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
Recommended Stories
- Five stocks we like better than Scancell
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
